2 years ago

clock.bio Launches with $4 Million in Funding for Age-Reversal Research

  • clock.bio, a Cambridge, UK-based longevity biotech company, launched out of stealth with $4 million in funding

  • The company is developing novel regenerative medicines leveraging the natural ability of human pluripotent stem cells to prevent and treat age-related diseases

  • The company's immediate scientific objective is to decode all rejuvenation programs present in human cells, to build an atlas of disease and rejuvenation targets for clinical translation

  • clock.bio has developed an aging model that force-ages human induced pluripotent stem cells (hiPSCs) and triggers their self-rejuvenation mechanism

  • Unbiased CRISPR screens on large samples of these cells allow for the identification of gene candidates that are causally relevant for cell rejuvenation.

      • ProblemHealthcare

      "Age-related diseases are a growing burden on society, and there is a need for new treatments that can prevent and treat these diseases."

      Solution

      "clock.bio is developing novel regenerative medicines leveraging the natural ability of human pluripotent stem cells to prevent and treat age-related diseases. They have developed an aging model that force-ages human induced pluripotent stem cells (hiPSCs) and triggers their self-rejuvenation mechanism. This allows them to identify gene candidates that are causally relevant for cell rejuvenation and develop therapeutic lead prioritization and translation into clinical applications."

      Covered on